These results indicated that the risk model constructed using HLA-DQA2, HOXA3, and SAA2 was not suitable for predicting the survival of wtIDH1 glioma patients and may be specific for IDH1mt-glioma patients. This evidence concerns the gene HLA-DQA2 and central nervous system cancer.